Tris Pharma
Executives
View the org chart displaying its 16 main executives
Most searched biographies at Tris Pharma
- Ketan Mehta, Chief Executive Officer and President
- Peter Ciano, Chief Financial Officer and Senior Vice President, Co...
- Cheryl Patnick, Senior Vice President, Human Resources and Adminis...
Popular executive movements at Tris Pharma
- Michael Magee has joined the company as Vice President, Quality and Compliance (posted on February 8 2024).
- Franchesca Fowler has joined the company as Chief Compliance Officer, Vice President and General Counsel (posted on January 22 2024).
Create your alert
to follow the executive moves at Tris Pharma.
Pharmaceuticals
Tris Pharma has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Tris Pharma
- Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD | Tris Pharma
- Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance | Tris Pharma
- Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel | Tris Pharma
- Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference | Tris Pharma
- Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder | Tris Pharma
- Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline | Tris Pharma
- Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD | Tris Pharma
- Tris Pharma® Hires Seasoned Business Development Executive Anthony Amato joins as Executive Vice President Business Development – Generics Division | Tris Pharma
- View more press releases Close
Social media about Tris Pharma
- Tris Pharma on Wikipedia, Google News & Yahoo Finance
- Tris Pharma on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Ketan Mehta 
